Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation
Open Access
- 23 April 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 32 (7), 1013-1024
- https://doi.org/10.1093/carcin/bgr075
Abstract
Mesothelin (MSLN) overexpression in pancreatic cancer (PC) leads to enhanced cell survival/proliferation and tumor progression. After screening for a number of growth factors/cytokines, we found that the MSLN expression correlated closely with interleukin (IL)-6 in human PC specimens and cell lines. Stably overexpressing MSLN in different PC cell lines (MIA-MSLN and Panc1-MSLN) led to higher IL-6 production. Silencing MSLN by small interfering RNA (siRNA) significantly reduced IL-6 levels. Blocking the observed constitutive activation of nuclear factor-kappaB (NF-κB) with IKK inhibitor wedelolactone in MIA-MSLN cells also reduced IL-6. Silencing IL-6 by siRNA reduced cell proliferation, cell cycle progression and induced apoptosis with significant decrease of c-myc/bcl-2. Interestingly, recombinant IL-6-induced proliferation of MIA-MSLN cells but not MIA-V cells. Although messenger RNA/protein levels of IL-6R did not vary, soluble IL-6R (sIL-6R) was significantly elevated in MIA-MSLN and was reduced by treatment with the TACE/ADAM17 inhibitor TAPI-1, indicating intramembrane IL-6R cleavage and IL-6 trans-signaling may be operative in MIA-MSLN cells. Blocking the IL-6/sIL-6R axis using sIL-6R antibody abrogated basal proliferation/survival as well as recombinant human IL-6-induced cell proliferation. Our data suggest that MSLN-activated NF-κB induces elevated IL-6 expression, which acts as a growth factor to support PC cell survival/proliferation through a novel auto/paracrine IL-6/sIL-6R trans-signaling. In addition, using a panel of PC cells with varying MSLN/IL-6 expressions, we showed that MSLN/IL-6 axis is a major survival axis in PC supporting tumor cell growth under anchorage-dependent and independent conditions. The close correlation between MSLN and IL-6 provides a new rationale for combination therapy for effective control of MSLN-overexpressing PCs.Keywords
This publication has 50 references indexed in Scilit:
- High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinomaBritish Journal of Cancer, 2009
- Inflammation and Cancer: IL-6 and STAT3 Complete the LinkCancer Cell, 2009
- Protein Kinase Cζ Represses the Interleukin-6 Promoter and Impairs Tumorigenesis In VivoMolecular and Cellular Biology, 2009
- Mesothelin-Induced Pancreatic Cancer Cell Proliferation Involves Alteration of Cyclin E via Activation of Signal Transducer and Activator of Transcription Protein 3Molecular Cancer Research, 2008
- The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancerTrends in Molecular Medicine, 2008
- Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancerMolecular Cancer Therapeutics, 2008
- Generation and characterization of an ascitogenic mesothelin-expressing tumor modelCancer, 2007
- The Inflammatory Cytokine Tumor Necrosis Factor-α Generates an Autocrine Tumor-Promoting Network in Epithelial Ovarian Cancer CellsCancer Research, 2007
- Expression profiling identifies microRNA signature in pancreatic cancerInternational Journal of Cancer, 2006
- Inflammation and cancerNature, 2002